JPMorgan analyst Eric Joseph lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $48 from $49 and keeps an Overweight rating on the shares following a model update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Biotech Alert: Searches spiking for these stocks today
- Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz
- American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls
- Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’
- Rocket Pharmaceuticals initiated with an Outperform at Wedbush